Drug delivery systems (DDS) using liposomes as drug carriers for targeting to macrophages have been developed for the treatment of diseases that macrophages are related to their progress. Initially, DDS for the treatment of atherosclerosis are described. The in‰uence of particle size on the drug delivery to atherosclerotic lesions that macrophages are richly present and antiatherosclerotic eŠects following intravenous administration of liposomes containing dexamethasone (DXM-liposomes) was investigated in atherogenic mice. Both the drug delivery e‹cacy of DXM-liposomes (particle size, 200 nm) to atherosclerotic lesions and their antiatherosclerotic eŠects were greater than those of 70 and 500 nm. These results indicate that there is an optimal particle size for drug delivery to atherosclerotic lesions. DDS for the treatment of respiratory infections are then described. The in‰uence of particle size and surface mannosylation on the drug delivery to alveolar macrophages (AMs) and antibacterial eŠects following pulmonary administration of liposomes containing cipro‰oxacin (CPFX-liposomes) was investigated in rats. The drug delivery e‹cacy of CPFX-liposomes to AMs was particle size-dependent over the range 100 1000 nm and then became constant at over 1000 nm. These results indicate that the most eŠective size is 1000 nm. Both the drug delivery e‹cacy of mannosylated CPFX-liposomes (particle size, 1000 nm) to AMs and their antibacterial eŠects were signiˆcantly greater than those of unmodiˆed CPFX-liposomes. These results indicate that the surface mannosylation is useful method for drug delivery to AMs. This review provides useful information to help in the development of novel pharmaceutical formulations aimed at drug targeting to macrophages.
DXM-liposomes were prepared with egg yolk phosphatidylcholine, cholesterol and dicetylphosphate in a lipid molar ratio of 7/2/1 by the hydration method and then adjusted to three diŠerent particle sizes by extrusion method. The particle sizes of DXM-liposomes were 69 nm, 202 nm and 519 nm, respectively. DXM concentration and DXM/lipid molar ratio in DXM-liposomes suspension were 1 mg DXM/ml and 0.134 mol DXM/mol total lipids, respectively. Atherogenic mice were prepared by giving atherogenic diet (6 g/day) containing 10％ linoleic acid, 1.5％ cholesterol, 0.5％ cholic acid, and 51.2％ sucrose for 14 weeks. DXM-liposomes or free DXM (2.5 mg DXM/kg) were intravenously administered to mice. At each time-point after administration, DXM in serum were determined and concentrations of DXM were calculated. Each value represents the mean±S.E. (n＝4). Macrophages obtained from murine peritoneal cavity and foam cells induced from macrophages by incubation with oxidized low-density lipoprotein were used. DXM-liposomes (25 nmol DXM/ml in medium) were added to cells, followed by incubation for 1 h at 37°C. After incubation, DXM and lipid marker in cells were determined and uptake e‹cacy of DXM and liposomes were calculated. Each value represents the mean±S.E. (n＝4). Column: (closeded), DXM; (open), liposomes. Details about DXM-liposomes used in this experiment are the same as those in Fig. 2 .
Fig. 5. Relationship between the Pharmacokinetics and Antiatherosclerotic EŠect of DXM in Atherogenic Mice
Atherogenic mice were maintained for 14 weeks on an atherogenic diet as described in Fig. 2 . DXM-liposomes or free DXM (55 mg DXM/kg) were intravenously administered to atherogenic mice once a week from 8 to 14 weeks. After 14 weeks, cholesterol ester level in aorta was determined and percentage of atherosclerotic inhibition was calculated. Mean residence time (MRT) and aortic uptake clearance (CL up ) of DXM were calculated from data shown in Fig. 2 CPFX-liposomes were prepared with hydrogenated soybean phosphatidylcholine, cholesterol and dicetylphosphate in a lipid molar ratio of 7/2/1 by the hydration method and then adjusted toˆve diŠerent particle sizes by extrusion method. The particle sizes of CPFX-liposomes were 93, 205, 405, 1094 and 2032 nm, respectively. CPFX concentration and CPFX/lipid molar ratio in CPFX-liposomes suspension were 0.8 mg CPFX/ml and 0.1 mol CPFX/mol total lipids, respectively. (A): Uptake proˆles of CPFX by NR8383 cells after application of CPFX-liposomes. CPFX-liposomes or free CPFX (100 nmol CPFX/ml in medium) were added to NR8383 cells, followed by incubation at 37°C. At each time-point after incubation, CPFX in NR8383 cells was determined and uptake e‹cacy of CPFX was calculated. Each value represents the mean±S.E. Unmodiˆed and mannosylated CPFX-liposomes were prepared with hydrogenated soybean phosphatidylcholine, dioleoyl phosphatidylcholine, cholesterol, dicetylphosphate and 4-aminophenyl-a-D-mannopyranoside in a lipid molar ratio of 3.5/3.5/2/1/0 or 3.5/3.5/2/1/1 by the hydration method and then adjusted to particle size by extrusion method. The particle sizes of unmodiˆed and mannosylated CPFX-liposomes were 1015 and 1005 nm, respectively. CPFX concentration and CPFX/lipid molar ratio in unmodiˆed or mannosylated CPFX-liposomes suspension were 0.8 mg CPFX/ml and 0.1 mol CPFX/mol total lipids, respectively. (A): Uptake proˆles of CPFX by NR8383 cells after application of unmodiˆed and mannosylated CPFX-liposomes. Unmodiˆed CPFX-liposomes, mannosylated CPFX-liposomes or free CPFX (100 nmol CPFX/ml in medium) were added to NR8383 cells, followed by incubation at 37°C. At each time-point after incubation, CPFX in NR8383 cells was determined and uptake e‹cacy of CPFX was calculated. Each value represents the mean±S.E. 
